Search PubMed⌕ Search

Biomedical subjects

L Asch

Publications and source records attributed to L Asch.

At least 55 records · Page 3Linked to original sources
PubMed1980

[Mechanism of fasting hyperuricemia].

The authors followed up 73 obese patients submitted to fasting for 7 days; 46 of them took nos drugs (control subjects); the others took daily 100 to 200 mg of benzbromarone. The average serum uric acid of the controls rose from 49.37 mg to 90.52 mg per litre. Their uric acid clearance during the week of fasting fell to 4.67 ml per minute. The uric acid turnover was multiplied by two and the mixable pool by 3.5. These results that the hyperuricemia of fasting is due both to a fall in uric acid clearance and increased catabolism of cellular nucleic acid.

Adolescent↗
PubMed1980

[Erythrocyte uric acid in the non-gouty subject].

The red cell uric acid concentration (E) is lower than its plasma concentration (P). In normal subjects the ration E/P is close to 0.7. Under experimental or pathological conditions (uricosuric treatment, fluid'diet, hemodialysis) causing changes in serum uric acid, the latter rises or falls proportionately less in red cells than in the plasma. There results a significant variation in the distribution of blood uric acid between the plasma and red cell compartments.

Benzbromarone↗
PubMed1978

[[Calciuria and phosphaturia during fasting. Effect of calcitonin alone or with a thyroid hormonotherapy combination].

The author compares 4 groups of obese individuals subjected to fasting for 7 days: Some took no medication, the others received either triiodothyronine (100 to 150 microgram per day), or calcitonin (1 unit MRC per day) or both triiodothyronine and calcitonin. An increase in calciuria and phosphaturia was observed with either triiodothyronine or calcitonin. Triiodothyronine in association with calcitonin did not increase further the calciuria caused by calcitonin but increased phosphaturia. The author offers an explanation for these various observations.

Adolescent↗
PubMed1976

[The action of somatotropic hormone on bone and on phospho-calcic metabolism].

The author reviews present knowledge concerning the action of somatotropic hormone on the kidney, the intestine, and on developmental changes in bone. He reviews, in particular, the controversial question of acromegalic osteoporosis and in this connexion considers the possibility of associated hyperparathyroidism.

Acromegaly↗